| Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer (NCT05043532) | Orlando Health, Inc. | 2021-08-18 |
| Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma (NCT04911816) | West Virginia University | 2021-07-16 |
| FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer (NCT04141995) | University of Nebraska | 2021-02-12 |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma (NCT04543071) | Gulam Manji | 2020-11-09 |
| Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (NCT03871959) | Centre Leon Berard | 2019-09-15 |
| Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B (NCT03778879) | Alan Katz | 2019-08-01 |
| Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas (NCT03490760) | Baptist Health South Florida | 2018-11-09 |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma (NCT03717298) | Catalysis SL | 2018-10-30 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (NCT02564146) | AIO-Studien-gGmbH | 2016-12-01 |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) (NCT02707328) | The Cooper Health System | 2015-01-01 |
| Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas (NCT02037230) | University of Michigan Rogel Cancer Center | 2014-01-01 |
| A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer (NCT02030860) | Abramson Cancer Center at Penn Medicine | 2014-01-01 |
| SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma (NCT01357525) | David A. Clump, MD, PhD | 2013-02-06 |
| A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer (NCT02707315) | The Cooper Health System | 2013-01-01 |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas (NCT01318642) | NantBioScience, Inc. | 2012-05-31 |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers (NCT01497392) | Roswell Park Cancer Institute | 2012-03-29 |
| Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy (NCT01484860) | University Health Network, Toronto | 2012-01-01 |
| Pancreatic Enzyme Suppletion in Pancreatic Cancer (NCT01401387) | Foundation for Liver Research | 2011-10-01 |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (NCT01231347) | NantCell, Inc. | 2011-04-07 |
| PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer (NCT01227018) | Vanderbilt-Ingram Cancer Center | 2010-12-01 |
| Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01222689) | National Cancer Institute (NCI) | 2010-11-01 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (NCT01233505) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer (NCT01232829) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer (NCT01192763) | National Cancer Institute (NCI) | 2010-08-01 |
| Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas (NCT00948688) | Massachusetts General Hospital | 2009-08-01 |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer (NCT00735917) | National Cancer Institute (NCI) | 2008-10-01 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer (NCT00577889) | National Cancer Institute (NCI) | 2008-03-01 |
| Perioperative Therapy for Resectable Pancreatic Cancer (NCT00609336) | University of Washington | 2008-01-01 |
| Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment (NCT00585845) | Anza Therapeutics, Inc. | 2007-12-01 |
| Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (NCT01068327) | University of Nebraska | 2007-11-05 |
| QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (NCT00630552) | NantCell, Inc. | 2007-06-01 |
| Dasatinib in Treating Patients With Metastatic Pancreatic Cancer (NCT00474812) | National Cancer Institute (NCI) | 2007-05-01 |
| Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer (NCT00375310) | Indiana University | 2006-09-01 |
| Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer (NCT00366457) | Massachusetts General Hospital | 2006-08-01 |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients (NCT00383760) | National Cancer Institute (NCI) | 2006-08-01 |
| Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer (NCT00331682) | National Cancer Institute (NCI) | 2006-03-01 |
| Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00114179) | National Cancer Institute (NCI) | 2005-01-01 |
| Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer (NCT00096070) | National Cancer Institute (NCI) | 2004-12-01 |
| Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer (NCT00091026) | National Cancer Institute (NCI) | 2004-07-01 |
| Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00088894) | National Cancer Institute (NCI) | 2004-06-01 |
| CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00075647) | National Cancer Institute (NCI) | 2003-12-01 |
| Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer (NCT00063947) | National Cancer Institute (NCI) | 2003-05-01 |
| Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer (NCT00047307) | National Cancer Institute (NCI) | 2002-08-01 |
| UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer (NCT00039403) | National Cancer Institute (NCI) | 2002-04-01 |
| Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer (NCT00028834) | National Cancer Institute (NCI) | 2002-02-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas (NCT00020345) | National Institutes of Health Clinical Center (CC) | 2000-09-01 |
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer (NCT00253526) | National Cancer Institute (NCI) | |